Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Chrysovalantou Chatzidimitriou
Observed names:
C. Chatzidimitriou,
Chrysovalanto Chatzidimitriou
Institutions:
National and Kapodistrian University of Athens,
Laiko General Hospital of Athens,
University General Hospital Attikon
Observed institutions:
National and Kapodistrian University of Athens,
Laiko General Hospital of Athens,
University General Hospital Attikon
ORCID:
0009-0003-8934-0342
Observed ORCID:
0009-0003-8934-0342
OpenAlex ID:
A5023008706
Immunotherapy in Hodgkin Lymphoma: Present Status and Future Strategies
2019
·
Theodoros P. Vassilakopoulos
, Chrysovalantou Chatzidimitriou
, et al.
·
Cancers
·
49
Prognostic Impact of Serum β2-Microglobulin Levels in Hodgkin Lymphoma Treated with ABVD or Equivalent Regimens: A Comprehensive Analysis of 915 Patients
2024
·
Theodoros P. Vassilakopoulos
, Maria Arapaki
, et al.
·
Cancers
·
13
PDF
Very late relapses in Hodgkin lymphoma treated with chemotherapy with or without radiotherapy: linear pattern and distinct prognostic factors
2022
·
Theodoros P. Vassilakopoulos
, Evrydiki Kravvariti
, et al.
·
Blood Cancer Journal
·
11
PDF
Serum ferritin levels in previously untreated classical Hodgkin lymphoma: correlations and prognostic significance
2022
·
Stamatios Karakatsanis
, Fotios Panitsas
, et al.
·
Leukemia & lymphoma/Leukemia and lymphoma
·
10
Rapidly deteriorating B-CLL at presentation: clonally related Burkitt leukemia as an atypical Richter transformation?
2021
·
Chrysovalantou Chatzidimitriou
, Theodoros P. Vassilakopoulos
·
Blood
·
9
PDF
PET for Response Assessment to R-da-EPOCH in Primary Mediastinal Large B-cell lymphoma: Who Is Worthy to be Irradiated?
2023
·
Theodoros P. Vassilakopoulos
, Alexia Piperidou
, et al.
·
HemaSphere
·
7
Validation of the simplified International Prognostic Score3 in a Hellenic cohort of patients with advanced‐stage Hodgkin‐lymphoma
2020
·
John V. Asimakopoulos
, Maria K. Angelopoulou
, et al.
·
British Journal of Haematology
·
7
Very Early Onset of Therapy-Related Acute Myeloid Leukemia with 11q23 Rearrangement Presenting with Unusual PET Findings after R-DA-EPOCH for Primary Mediastinal Large B-Cell Lymphoma
2021
·
Chrysovalantou Chatzidimitriou
, Phivi Rondogianni
, et al.
·
Medicina
·
5
PDF
Pf297 Comparison of Rituximab Dose‐adjusted Epoch (r‐da‐epoch) With Rituximab‐chop (r‐chop) Chemotherapy in Primary Mediastinal Large B‐cell Lymphoma (pmlbcl)
2019
·
T. Vassilakopoulos
, Z. Mellios
, et al.
·
HemaSphere
·
5
Rituximab‐dose‐adjusted Epoch (r‐da‐epoch) in Primary Mediastinal Large B‐cell Lymphoma (pmlbcl): Real‐life Experience on 190 Patients From 3 Mediterranean Countries
2021
·
T. Vassilakopoulos
, B. Ferhanoglu
, et al.
·
Hematological Oncology
·
4
PDF
Optimally Delivered R-da-EPOCH Versus R-CHOP-21 in Primary Mediastinal Large B-Cell Lymphoma: A Real-Life Comparison in a Single Academic Center
2025
·
Alexia Piperidou
, Maria K. Angelopoulou
, et al.
·
Cancers
·
3
PDF
Successful salvage of primary progressive Hodgkin lymphoma with the combination of post‐transplant brentuximab vedotin and radiotherapy: Combining novelty and tradition
2020
·
Marina Belia
, Chrysovalantou Chatzidimitriou
, et al.
·
Hematological Oncology
·
3
REAL‐LIFE EXPERIENCE WITH RITUXIMAB‐DOSE‐ADJUSTED EPOCH (R‐da‐EPOCH) IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (PMLBCL): A MULTINATIONAL ANALYSIS OF 274 PATIENTS
2023
·
T. Vassilakopoulos
, B. Ferhanoglu
, et al.
·
Hematological Oncology
·
2
PDF
The Impact of Chemotherapy on Gonadal Function in Female Patients with Hodgkin and Non-Hodgkin Lymphoma: A Comprehensive Analysis of Hormonal Kinetics and Implications for Fertility and Contraceptive Planning
2026
·
Angeliki N. Georgopoulou
, Theodoros P. Vassilakopoulos
, et al.
·
Cancers
·
1
Real‐World Outcomes in NPM1 ‐Mutated Acute Myeloid Leukemia: The Impact of Measurable Residual Disease on Disease Relapse
2026
·
Panagiotis Tsirigotis
, Maria Garofalaki
, et al.
·
American Journal of Hematology
·
1
Treatment Strategies and Prognostic Factors for the Outcome of Patients With Hodgkin Lymphoma Experiencing Very Late Relapses After Chemotherapy ± Radiotherapy
2023
·
T. P. Vassilakopoulos
, A. Liaskas
, et al.
·
Hematological Oncology
·
1
PDF
P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
2022
·
Theodoros P. Vassilakopoulos
, Athanasios Liaskas
, et al.
·
HemaSphere
·
1
P1229: Rituximab-dose-adjusted Epoch (r-da-epoch) in Primary Mediastinal Large B-cell Lymphoma (pmlbcl): Real-life Experience on 225 Patients From 4 Countries
2022
·
T. Vassilakopoulos
, B. Ferhanoglu
, et al.
·
HemaSphere
·
1
P1230: Pet/ct Imaging for Response Assessment and Treatment Guidance After Rituximab-dose-adjusted-epoch(r-da-epoch) in Primary Mediastinal Large B-cell Lymphoma (pmlbcl):the Greek Experience on 107 Patients
2022
·
T. Vassilakopoulos
, A. Piperidou
, et al.
·
HemaSphere
·
1
Pancytopenia, eosinophilia and coagulation disorders in a patient with T‐acute lymphoblastic leukemia in prolonged remission
2021
·
Chrysovalantou Chatzidimitriou
, Vasiliki Pappa
, et al.
·
American Journal of Hematology
·
1
PDF
Ps1089 Pet-scan for Response Assessement After Rituximab-dose-adjusted-epoch (r-da-epoch) in Primary Mediastinal Large B-cell Lymphoma (pmlbcl): Clinical and Prognostic Significance
2019
·
T. Vassilakopoulos
, C. Chatzidimitriou
, et al.
·
HemaSphere
·
1
Pf472 Very Late Realapses (vlr) ≥5 Years After Initial Treatment With Chemotherapy±radiotherapy (ct±rt) in Hodgkin Lymphoma (hl): a Join Study on Treatment Strategies and Prognostic Factors for the Outcome
2019
·
T. Vassilakopoulos
, A. Liaskas
, et al.
·
HemaSphere
·
1
PDF
Gilteritinib for Prevention of Post-transplant Relapse in Patients With Acute Myeloid Leukemia and FLT3-ITD Mutation: Real-Life Data from Two Centers
2026
·
Panagiotis Tsirigotis
, Ioanna Lazana
, et al.
·
Transplantation and Cellular Therapy
344 | SERUM β2‐ MICROGLOBULIN LEVELS IN PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA: AN UNRECOGNIZED PROGNOSTIC FACTOR
2025
·
T. Vassilakopoulos
, M. Arapaki
, et al.
·
Hematological Oncology
PDF
346 | Rituximab‐dose‐adjusted Epoch Versus Rituximab‐chop in Primary Mediastinal Large B‐cell Lymphoma
2025
·
T. Vassilakopoulos
, Z. Mellios
, et al.
·
Hematological Oncology
PDF
Show more works
View as search
Works count:
29
Citation count:
137
H-index:
7
I10-index:
4
Year
Topic
Type